Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6765117 | UNITED THERAP | Process for stereoselective synthesis of prostacyclin derivatives |
Oct, 2017
(6 years ago) | |
US9050311 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(26 days from now) | |
US7417070 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2026
(2 years from now) | |
US9593066 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in remodulin® |
Dec, 2028
(4 years from now) | |
US11723887 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
US9604901 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
US8497393 | UNITED THERAP | Process to prepare treprostinil, the active ingredient in Remodulin® |
Dec, 2028
(4 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5153222 | UNITED THERAP | Method of treating pulmonary hypertension with benzidine prostaglandins |
Oct, 2014
(9 years ago) | |
US9278901 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(26 days from now) | |
US8252839 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(26 days from now) | |
US9422223 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
May, 2024
(26 days from now) | |
US7544713 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Jul, 2024
(2 months from now) | |
US9393203 | UNITED THERAP | Osmotic drug delivery system |
Apr, 2026
(1 year, 11 months from now) | |
US8410169 | UNITED THERAP | Compounds and methods for delivery of prostacyclin analogs |
Feb, 2030
(5 years from now) | |
US8349892 | UNITED THERAP | Solid formulations of prostacyclin analogs |
Jan, 2031
(6 years from now) | |
US8747897 | UNITED THERAP | Osmotic drug delivery system |
Aug, 2031
(7 years from now) |
Orenitram is owned by United Therap.
Orenitram contains Treprostinil Diolamine.
Orenitram has a total of 16 drug patents out of which 2 drug patents have expired.
Expired drug patents of Orenitram are:
Orenitram was authorised for market use on 20 December, 2013.
Orenitram is available in tablet, extended release;oral dosage forms.
Orenitram can be used as a method of oral delivery of treprostinil comprising administering an oral osmotic pharmaceutical dosage form, use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1)., method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically acceptable salt of treprostinil.
The generics of Orenitram are possible to be released after 11 August, 2031.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity(ODE-272) | Oct 18, 2026 |
New Dosage Form(NDF) | Dec 20, 2016 |
New Indication(I-820) | Oct 18, 2022 |
New Dosing Schedule(D-156) | Jan 28, 2019 |
New Dosing Schedule(D-157) | Jan 28, 2019 |
Orphan Drug Exclusivity(ODE-308) | Dec 20, 2020 |
Drugs and Companies using TREPROSTINIL DIOLAMINE ingredient
Market Authorisation Date: 20 December, 2013
Treatment: Use of orenitram for the treatment of pulmonary arterial hypertension (pah) (who group 1).; Method of treating pulmonary hypertension by orally administering a formulation of a pharmaceutically accept...
Dosage: TABLET, EXTENDED RELEASE;ORAL